<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387022</url>
  </required_header>
  <id_info>
    <org_study_id>CAPRISA 009</org_study_id>
    <nct_id>NCT01387022</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression</brief_title>
  <acronym>TOAST</acronym>
  <official_title>Open Label Randomized Controlled Trial to Assess the Impact of Prophylactic Exposure to Tenofovir Gel on the Efficacy of Subsequent Tenofovir-containing Antiretroviral Therapy on Viral Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for the AIDS Programme of Research in South Africa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for the AIDS Programme of Research in South Africa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HIV/AIDS pandemic remains among the investigators greatest public health challenges. In
      the absence of an effective vaccine, focus has shifted to other prevention strategies such as
      pre-exposure prophylaxis. Tenofovir, with potent activity against retroviruses [1], was
      developed for oral use as Viread速, which is widely used for HIV treatment. The efficacy of
      Viread速 has been demonstrated in treatment-experienced and na誰ve patients [2,3]. In
      antiretroviral-naive patients, the combination of tenofovir with lamivudine and efavirenz has
      been classified as a preferred regimen in the Department of Health and Human Services
      treatment guidelines[4], and has been adopted by the South African Department of health as
      the first line regimen in treatment-na誰ve HIV infected patients since April 2010. The
      durability of antiviral response, favourable resistance profile, once daily dosing, and
      excellent long term safety profile of tenofovir [5], makes this drug an attractive option in
      both treatment and prevention regimens and its long half-life [6], made it an ideal choice as
      the first antiretroviral drug to be formulated as a microbicide gel.

      The CAPRISA 004 study conducted in South Africa which tested the effectiveness and safety of
      1% tenofovir gel showed that the use of tenofovir in a gel formulation reduced HIV
      acquisition by 39% overall, and by 54% in women with high gel adherence [7]. There have been
      concerns raised regarding the use of tenofovir in both PrEP and treatment regimens due to the
      potential for selection of viral mutations and development of resistance in patients who have
      become HIV-infected while on PrEP.

      There have been no studies conducted to determine whether using tenofovir in pre-exposure
      prophylaxis affects treatment outcomes in patients who later use tenofovir, which is part of
      the first line ART of South Africa.

      This study aims to determine whether prophylactic exposure to tenofovir gel alters the
      therapeutic response to a tenofovir containing antiretroviral regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      To determine whether prophylactic exposure to tenofovir gel alters the therapeutic response
      to a tenofovir containing antiretroviral regimen

      Study design:

      Open label, two-arm, randomised controlled trial

      Study population:

      Women who become infected with HIV while participating in the CAPRISA 004 and CAPRISA 008
      trials. There are 3 study populations:

      Study population 1:

      HIV positive women from the CAPRISA 004 tenofovir gel arm and HIV positive women from the
      clinical trial tenofovir gel provision arm of CAPRISA 008

      Study population 2:

      HIV positive women in the placebo arm of CAPRISA 004

      Study population 3:

      HIV positive women from the family planning service arm of CAPRISA 008

      Study sites:

      CAPRISA eThekwini and CAPRISA Vulindlela clinics.

      Study duration:

      3 years

      Study intervention:

      Enrolled women will be initiated on their assigned antiretroviral therapy regimen when they
      reach any of the following criteria:

        -  reach a CD4+ count of less than 350 cell/mm3

        -  acquire an AIDS defining illness

        -  become pregnant - women in any of the three study populations who become pregnant during
           follow-up will be initiated on their assigned treatment regimen, as appropriate, for
           prevention of mother-to-child transmission of HIV.

      At enrolment women in each of the three study populations will be assigned randomly to one of
      the two following antiretroviral regimens Intervention Arm: Tenofovir, lamivudine and
      efavirenz Control arm: Zidovudine, lamivudine and efavirenz

      Sample size: The projected sample size is 90 women. The number of women in each stratum is as
      follows:

      Study population 1: n = 40 Study population 2: n = 30 Study population 3: n = 20

      Primary endpoint:

      The primary endpoint is the antiretroviral treatment failure rate at 12 months. Treatment
      failure is defined as viral load &gt; 50 copies/ml, antiretroviral regimen changes for treatment
      failure or death

      Secondary Endpoints:

        1. Change in CD4+ cell count from the earliest post-infection timepoint to the time of
           randomisation to 12, 24 and 36 months post-randomisation

        2. Tenofovir resistance, defined as presence of K65R, K70E or any of the TAMS mutations.

        3. Reported adverse events with severity grades 3 and 4 based on the DAIDS toxicity grading
           tables

        4. Cellular and humoral immune responses

        5. Genital viral shedding (viral load on tear flow) Ancillary Endpoint Mother-to-child HIV
           transmission rates as determined by PCR on infant at 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Antiretroviral Treatment Failure Rate at 12 Months.</measure>
    <time_frame>12 months post ART intiation or until time of death</time_frame>
    <description>Treatment failure is defined as viral load &gt; 50 copies/ml, antiretroviral regimen changes for treatment failure or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ Cell Count From Randomisation to 12 Months Post-randomisation</measure>
    <time_frame>Measured at 12 months post ART initiation</time_frame>
    <description>Difference between 12 months and randomisation CD4+ count was calculated and then summarised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tenofovir Resistance, Defined as Presence of K65R, K70E or Any of the TAMS Mutations</measure>
    <time_frame>From randomisation until either time of termination or time of death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reported Adverse Events With Severity Grades 3 and 4 Based on the DAIDS Toxicity Grading Tables</measure>
    <time_frame>From randomisation until either time of termination or time of death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular and Humoral Immune Responses</measure>
    <time_frame>3 years</time_frame>
    <description>We will assess whether exposure to tenofovir gel at the time of HIV acquisition alters the subsequent humoral and cellular immune responses following antiretroviral treatment initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genital Viral Shedding (Viral Load on Tear Flow)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Antiretroviral Treatment Outcomes</condition>
  <arm_group>
    <arm_group_label>Tenofovir, lamivudine and efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zidovudine, lamivudine and efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir, lamivudine and efavirenz</intervention_name>
    <description>Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong</description>
    <arm_group_label>Tenofovir, lamivudine and efavirenz</arm_group_label>
    <arm_group_label>Zidovudine, lamivudine and efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Previously enrolled in the CAPRISA 004 or CAPRISA 008 study - placebo or active arms

          -  Able and willing to provide informed consent to be screened for, and to enrol in, the
             study

          -  Able and willing to provide adequate locator information for study retention purposes

          -  Confirmed HIV infection in the CAPRISA 004 or 008 trial

          -  Agree to adhere to study visits and procedures

        Exclusion Criteria:

          -  Currently on antiretroviral therapy (including PMTCT prophylaxis)

          -  Has any other condition that, based on the opinion of the Investigator or designee,
             would preclude provision of informed consent, make participation in the study unsafe,
             complicate interpretation of study outcome data, or otherwise interfere with achieving
             the study objectives.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nivashnee Naicker, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for the AIDS Programme of Research in South Africa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CAPRISA</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4000</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol. 2007 Apr 1;73(7):911-22. Epub 2006 Sep 19.</citation>
    <PMID>17045247</PMID>
  </reference>
  <reference>
    <citation>Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK; Study 902 Team. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002 Jun 14;16(9):1257-63.</citation>
    <PMID>12045491</PMID>
  </reference>
  <reference>
    <citation>Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A; Study 907 Team. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003 Sep 2;139(5 Pt 1):313-20.</citation>
    <PMID>12965939</PMID>
  </reference>
  <reference>
    <citation>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. Available from: www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed 9 November 2010.</citation>
  </reference>
  <reference>
    <citation>Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004 Jul 14;292(2):191-201.</citation>
    <PMID>15249568</PMID>
  </reference>
  <reference>
    <citation>Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, Billitto N, Lynam JD, Pryke K, Graebing P, Hopkins N, Rooney JF, Friend D, Dezzutti CS. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One. 2010 Feb 19;5(2):e9310. doi: 10.1371/journal.pone.0009310.</citation>
    <PMID>20174579</PMID>
  </reference>
  <reference>
    <citation>Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.</citation>
    <PMID>20643915</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2011</study_first_posted>
  <results_first_submitted>January 30, 2017</results_first_submitted>
  <results_first_submitted_qc>January 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2017</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for the AIDS Programme of Research in South Africa</investigator_affiliation>
    <investigator_full_name>Dr Salim S Abdool Karim</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Antiretroviral treatment</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Drug resistance</keyword>
  <keyword>Treatment outcome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Two arm, open-label, randomised controlled trial</recruitment_details>
      <pre_assignment_details>A total of 214 participants were assessed for eligibility: 60 were excluded due to high CD4+ count, 30 were already on ART, 8 were loss to follow-up and 43 refused participation. Of the 73 that were screened, 8 were screen failures due to high CD4+ count, 4 refused participation, 1 was very ill with TB and 1 could not be contacted.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tenofovir-containing Regimen</title>
          <description>Patients were initiated on EFV, FTC/3TC,TDF</description>
        </group>
        <group group_id="P2">
          <title>Tenofovir-sparing Regimen</title>
          <description>Patients were initiated on EFV,FTC/3TC,ZDV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who were randomised and initiated on ART</population>
      <group_list>
        <group group_id="B1">
          <title>Tenofovir-containing Regimen</title>
          <description>Patients were initiated on EFV, FTC/3TC,TDF</description>
        </group>
        <group group_id="B2">
          <title>Tenofovir-sparing Regimen</title>
          <description>Patients were initiated on EFV,FTC/3TC,ZDV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="25" upper_limit="33"/>
                    <measurement group_id="B2" value="28" lower_limit="26" upper_limit="30"/>
                    <measurement group_id="B3" value="28" lower_limit="25" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T cell count</title>
          <units>cells/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="345" lower_limit="289" upper_limit="431"/>
                    <measurement group_id="B2" value="335" lower_limit="280" upper_limit="411"/>
                    <measurement group_id="B3" value="345" lower_limit="280" upper_limit="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Viral load</title>
          <units>log10 copies/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" spread="0.79"/>
                    <measurement group_id="B2" value="4.6" spread="0.80"/>
                    <measurement group_id="B3" value="4.5" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Antiretroviral Treatment Failure Rate at 12 Months.</title>
        <description>Treatment failure is defined as viral load &gt; 50 copies/ml, antiretroviral regimen changes for treatment failure or death</description>
        <time_frame>12 months post ART intiation or until time of death</time_frame>
        <population>All participants who randomised and initiated on ART</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir-containing Regimen</title>
            <description>Patients were initiated on EFV, FTC/3TC,TDF</description>
          </group>
          <group group_id="O2">
            <title>Tenofovir-sparing Regimen</title>
            <description>Patients were initiated on EFV,FTC/3TC,ZDV</description>
          </group>
        </group_list>
        <measure>
          <title>The Antiretroviral Treatment Failure Rate at 12 Months.</title>
          <description>Treatment failure is defined as viral load &gt; 50 copies/ml, antiretroviral regimen changes for treatment failure or death</description>
          <population>All participants who randomised and initiated on ART</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4+ Cell Count From Randomisation to 12 Months Post-randomisation</title>
        <description>Difference between 12 months and randomisation CD4+ count was calculated and then summarised</description>
        <time_frame>Measured at 12 months post ART initiation</time_frame>
        <population>All participants for whom CD4+ count measurements were recorded at randomisation and at 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir-containing Regimen</title>
            <description>Patients were initiated on EFV, FTC/3TC,TDF</description>
          </group>
          <group group_id="O2">
            <title>Tenofovir-sparing Regimen</title>
            <description>Patients were initiated on EFV,FTC/3TC,ZDV</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4+ Cell Count From Randomisation to 12 Months Post-randomisation</title>
          <description>Difference between 12 months and randomisation CD4+ count was calculated and then summarised</description>
          <population>All participants for whom CD4+ count measurements were recorded at randomisation and at 12 months</population>
          <units>cells/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217" lower_limit="52" upper_limit="272"/>
                    <measurement group_id="O2" value="174" lower_limit="70" upper_limit="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.481</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tenofovir Resistance, Defined as Presence of K65R, K70E or Any of the TAMS Mutations</title>
        <time_frame>From randomisation until either time of termination or time of death</time_frame>
        <population>Resistance testing was only done on participants who were failing first line antiretroviral therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir-containing Regimen</title>
            <description>Patients were initiated on EFV, FTC/3TC,TDF</description>
          </group>
          <group group_id="O2">
            <title>Tenofovir-sparing Regimen</title>
            <description>Patients were initiated on EFV,FTC/3TC,ZDV</description>
          </group>
        </group_list>
        <measure>
          <title>Tenofovir Resistance, Defined as Presence of K65R, K70E or Any of the TAMS Mutations</title>
          <population>Resistance testing was only done on participants who were failing first line antiretroviral therapy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reported Adverse Events With Severity Grades 3 and 4 Based on the DAIDS Toxicity Grading Tables</title>
        <time_frame>From randomisation until either time of termination or time of death</time_frame>
        <population>All participants who randomised and initiated on ART</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir-containing Regimen</title>
            <description>Patients were initiated on EFV, FTC/3TC,TDF</description>
          </group>
          <group group_id="O2">
            <title>Tenofovir-sparing Regimen</title>
            <description>Patients were initiated on EFV,FTC/3TC,ZDV</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Adverse Events With Severity Grades 3 and 4 Based on the DAIDS Toxicity Grading Tables</title>
          <population>All participants who randomised and initiated on ART</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.267</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cellular and Humoral Immune Responses</title>
        <description>We will assess whether exposure to tenofovir gel at the time of HIV acquisition alters the subsequent humoral and cellular immune responses following antiretroviral treatment initiation</description>
        <time_frame>3 years</time_frame>
        <population>Data were not collected for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir-containing Regimen</title>
            <description>Patients were initiated on EFV, FTC/3TC,TDF</description>
          </group>
          <group group_id="O2">
            <title>Tenofovir-sparing Regimen</title>
            <description>Patients were initiated on EFV,FTC/3TC,ZDV</description>
          </group>
        </group_list>
        <measure>
          <title>Cellular and Humoral Immune Responses</title>
          <description>We will assess whether exposure to tenofovir gel at the time of HIV acquisition alters the subsequent humoral and cellular immune responses following antiretroviral treatment initiation</description>
          <population>Data were not collected for this Outcome Measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genital Viral Shedding (Viral Load on Tear Flow)</title>
        <time_frame>3 years</time_frame>
        <population>Data were not collected for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir-containing Regimen</title>
            <description>Patients were initiated on EFV, FTC/3TC,TDF</description>
          </group>
          <group group_id="O2">
            <title>Tenofovir-sparing Regimen</title>
            <description>Patients were initiated on EFV,FTC/3TC,ZDV</description>
          </group>
        </group_list>
        <measure>
          <title>Genital Viral Shedding (Viral Load on Tear Flow)</title>
          <population>Data were not collected for this Outcome Measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>19 July 2011 to 30 September 2014</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tenofovir-containing Regimen</title>
          <description>Patients were initiated on EFV, FTC/3TC,TDF</description>
        </group>
        <group group_id="E2">
          <title>Tenofovir-sparing Regimen</title>
          <description>Patients were initiated on EFV,FTC/3TC,ZDV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlactacidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign hydatidiform mole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Delivery</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abscess drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Caesarean section</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Female sterilisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The main limitation of the study was the small sample size. The eligible pool of participants was dependent on two other tenofovir gel trials, one of which experienced long delay in starting.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Head of Statistics and Data Management</name_or_title>
      <organization>CAPRISA</organization>
      <phone>+27 31 260 4392</phone>
      <email>nonhlanhla.yende@caprisa.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

